Shire to compare Vyvanse with competing drug in phase-4 trial program

PHILADELPHIA — Drug maker Shire will conduct two post-marketing trials to compare its treatment for attention deficit hyperactivity disorder with a competing drug, the company said Tuesday.



Shire announced that it would start two phase-4 trials comparing its drug, Vyvanse (lisdexamfetamine dimesylate), with Alza's Concerta (methylphenidate hydrochloride).



Shire said the purpose of the trials was to find out possible differences in efficacy between the drugs and said such trials would provide important information to physicians, patients, caregivers and payers.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.